SML2259

Lapatinib

≥98% (HPLC), EGFR/ErbB1 and HER2/ErbB2 inhibitor, powder

• Synonym(e): Lapatinib, GD 2016, GSK 572016, GW-572016, GW572016, N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine, N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
• Empirische Formel (Hill-System): C₂₉H₂₆ClFN₄O₄S
• CAS-Nummer: 231277-92-2
• Molekulargewicht: 581.06
• NACRES: NA.77
• UNSPSC Code: 12352200
• MDL number: MFCD09264194
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Produktname: Lapatinib, ≥98% (HPLC)
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O
• InChI: 1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
• InChI key: BCFGMOOMADDAQU-UHFFFAOYSA-N
• Gene Information: human ... EGFR(1956), ERBB2(2064)

Beschreibung

Biochem/physiol Actions

Lapatinib acts as a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2). It competes for its binding site on the tyrosine kinase domain with adenosine triphosphate (ATP). Lapatinib mediates has been studied in vitro in the inhibition of cell growth as well as and apoptosis induction in several human cancer cells such as breast, lung, vulva, gastric, and head and neck cancer.

Sicherheitshinweise

• pictograms: GHS08
• signalword: Warning
• hcodes: H361d,H362,H373,H413
• Lagerklasse: 11 - Combustible Solids
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• target_organs: Liver
• pcodes: P202 - P260 - P263 - P264 - P273 - P308 + P313
• Hazard Classifications: Aquatic Chronic 4 - Lact. - Repr. 2 - STOT RE 2